Answer
Momelotinib inhibits BCRP; multiple doses of 200 mg once daily increased a single 10 mg rosuvastatin dose’s peak concentration 3.2-fold and overall exposure 2.7-fold, potentially increasing rosuvastatin adverse reactions.
Sources for this answer
- Omjjara 150 mg film-coated tabletsGlaxoSmithKline UK · emc · SmPC §4.5 Interaction with other medicinal products · Version 4Document updated
Sources checked